Brief Report: Durable Suppression and Low Rate of Virologic Failure 3 Years After Switch to Dolutegravir + Rilpivirine 2-Drug Regimen: 148-Week Results From the SWORD-1 and SWORD-2 Randomized Clinical Trials

BACKGROUND: The SWORD trials showed that in participants who achieved virologic suppression taking 3-drug or 4-drug regimens, switching to the 2-drug regimen dolutegravir plus rilpivirine was noninferior in maintaining HIV-1 RNA <50 copies/mL at the week 48 primary endpoint. We present pooled wee...

Descripción completa

Detalles Bibliográficos
Autores principales: van Wyk, Jean, Orkin, Chloe, Rubio, Rafael, Bogner, Johannes, Baker, David, Khuong-Josses, Marie-Aude, Parks, David, Angelis, Konstantinos, Kahl, Lesley P., Matthews, Jessica, Wang, Ruolan, Underwood, Mark, Wynne, Brian, Nascimento, Maria-Claudia, Vandermeulen, Kati, Gartland, Martin, Smith, Kimberly Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: JAIDS Journal of Acquired Immune Deficiency Syndromes 2020
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7446981/
https://www.ncbi.nlm.nih.gov/pubmed/32675772
http://dx.doi.org/10.1097/QAI.0000000000002449

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7446981/
https://www.ncbi.nlm.nih.gov/pubmed/32675772
http://dx.doi.org/10.1097/QAI.0000000000002449

Ejemplares similares